Anti-Amyloid Still All The RAGE At Alzheimer’s Disease Conference
Executive Summary
A little more than a week after an article published in The Lancet raised questions about the assumption that removing amyloid plaque is key to modifying Alzheimer's disease - an assumption upon which most drug makers are pinning their hopes - Wyeth, Lilly and Pfizer unveiled data on their respective agents at the International Conference on Alzheimer's Disease in Chicago
You may also be interested in...
Elan Insists Remaining Alzheimer's Portfolio Has Deep Roots And New Shoots
Now that Elan has sold its immunotherapy-based drug candidates for Alzheimer's disease to Johnson & Johnson, management says it wants to focus even more intensely on the remaining pipeline, including a series of early-stage drug candidates related to Alzheimer's
Elan Insists Remaining Alzheimer's Portfolio Has Deep Roots And New Shoots
Now that Elan has sold its immunotherapy-based drug candidates for Alzheimer's disease to Johnson & Johnson, management says it wants to focus even more intensely on the remaining pipeline, including a series of early-stage drug candidates related to Alzheimer's
Elan Insists Remaining Alzheimer's Portfolio Has Deep Roots And New Shoots
Now that Elan has sold its immunotherapy-based drug candidates for Alzheimer's disease to Johnson & Johnson, management says it wants to focus even more intensely on the remaining pipeline, including a series of early-stage drug candidates related to Alzheimer's